Semaglutide Sources: Where the Medicine in Wegovy Actually Comes From

Step 1, Novo Nordisk manufactures semaglutide and it enters the licensed UK supply chain

Semaglutide is a GLP-1 receptor agonist, a synthetic analogue of a naturally occurring gut hormone. Novo Nordisk developed the molecule and holds the marketing authorisations for its weight-management brand, Wegovy, in the UK. The MHRA (not the European Medicines Agency) is the body that authorises medicines in Great Britain, and Wegovy's approval here was granted separately to any EU decision.

From the manufacturing site, finished product moves through Novo Nordisk's authorised wholesale distribution network. Wholesalers holding a Wholesale Dealer's Authorisation (WDA) are the only entities permitted to supply pharmacies. This chain is documented, audited and traceable. A pen that has not passed through it cannot be verified as genuine, regardless of how it looks or what the packaging claims.

There is currently no biosimilar semaglutide licensed in the UK for weight management. Compounded or "pharmacy-made" semaglutide is not an MHRA-authorised product; the MHRA has been clear that unlicensed compounded GLP-1 products are not subject to the same quality and safety standards. When you see semaglutide advertised at a fraction of the going market rate, the supply chain question is exactly what should be asked first.

Step 2, A GPhC-registered pharmacy receives and dispenses it, against a valid prescription

The next link in the chain is the pharmacy. In the UK, a pharmacy must be registered with the General Pharmaceutical Council (GPhC) to dispense prescription medicines. You can check any pharmacy (including online pharmacies) on the GPhC register at pharmacyregulation.org/registers. If a seller cannot be found there, it should not be supplying semaglutide to UK patients.

Dispensing also requires a valid prescription issued by a prescriber registered with a UK regulatory body. The prescription must be generated following a genuine clinical assessment, not a tick-box form with no follow-up, and not a process designed to make approval automatic. The NHS medicines page for semaglutide sets out the clinical context clearly, including the conditions it is and is not licensed to treat.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not a screening algorithm) before any prescription is issued. The pharmacy holding GPhC premises registration 9012878 then dispenses from the licensed supply chain. That sequence is not optional; it is what makes the supply legitimate.

Step 3, The prescription is issued for the right licensed product, at the right licensed indication

This step is worth pausing on, because semaglutide appears under more than one brand name for different conditions. Wegovy is licensed for weight management. Ozempic contains the same molecule but is licensed for type 2 diabetes, not weight loss. Rybelsus is an oral formulation of semaglutide licensed for type 2 diabetes. The three are not interchangeable for prescribing purposes, and a prescriber who issues Ozempic to treat obesity is acting outside that product's licensed indication.

In June 2026, the MHRA approved Wegovy tablets (oral semaglutide) as the first oral GLP-1 medicine licensed in the UK for weight management. This is a separate product from Rybelsus; the tablet strengths are different and the dosing ladder is different. For anyone reading about semaglutide for weight loss, the brand name and the indication on the prescription both matter. A thorough overview of what Wegovy covers (including the newer 7.2mg pen approved in April 2026) is on our Wegovy treatment page.

If you are mid-way through treatment and wondering about a specific dose, the semaglutide 2mg page covers dose-context questions in detail. Patients earlier in their titration journey can find guidance on our semaglutide 1mg page, while those who have progressed further into the dosing schedule will find our semaglutide 3mg page useful for what to expect at that stage. Questions about how to start the process (including eligibility) are answered on our how to get Wegovy online page. Pricing context, which matters when evaluating different sources, is covered on the weight-loss treatments page.

Why the source of your semaglutide is a clinical safety issue, not just a paperwork one

The MHRA has warned publicly and repeatedly about counterfeit weight-loss pens circulating in the UK. Fake pens seized in enforcement operations have in some cases been found to contain insulin rather than the stated medicine, a substance that could cause life-threatening hypoglycaemia in someone not living with diabetes. These are not edge-case concerns; approximately 20 million doses of illegally traded weight-loss medicines with an estimated street value of around £45 million were seized during 2025 enforcement activity, and the first illicit UK site producing counterfeit tirzepatide pens was identified in Northampton in October 2025.

You can report suspect sellers directly to the MHRA using the Yellow Card scheme, which also accepts reports of suspected side effects. Red flags to watch for: sellers who do not require a prescription or clinical review before supplying; prices significantly below the established market range; social media sellers; and any pharmacy you cannot verify on the GPhC register. A small saving is not worth what is at stake when the product goes under your skin.

Our about us page explains how our dispensing process works and why we source exclusively through the authorised UK supply network. If you have questions our FAQs cover common concerns, or you can reach us directly via our contact page. When you are ready, checking your eligibility takes a few minutes and costs nothing.